Safety and Suitability of an Infant Formula Manufactured from Extensively Hydrolysed Protein in Healthy Term Infants
Nutrients · 2023
DOI: 10.3390/nu15081901 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Lindsey Otten und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Evangelisches Waldkrankenhaus Spandau, Stadtrandstr. 555, 13589 Berlin, Germany. Hauptthemen laut MEDLINE: Infant Formula, Milk Hypersensitivity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HiPP GmbH & Co. Vertrieb KG.
Abstract (Originalsprache)
We aimed to demonstrate that healthy term infants experience noninferior growth with infant formula manufactured from extensively hydrolysed whey protein (eHF) compared to intact cow’s milk protein (control formula, CF). This prospective, randomised, double-blind, parallel-group, controlled, multicentre trial included healthy term infants who were exclusively formula-fed. Infants ≤ 25 days of age received eHF or CF for at least three months up to 120 days of age, with a follow-up until 180 days of age. A reference group included exclusively breastfed infants (BF). Of 318 infants randomised, 297 (148 CF, 149 eHF) completed the study per protocol. Weight gain up to 120 days of age was noninferior (margin −3.0 g/day) in eHF (28.95 (95% CI: 27.21; 30.68) g/day) compared to CF (28.85 (95% CI: 27.10; 30.61) g/day) with a difference in means of 0.09 g/day and a lower limit of the one-sided 97.5% CI of −0.86 g/day (p < 0.0001 for noninferiority testing). Weight gain remained comparable during follow-up. Further anthropometric parameters did not differ between the infant formula groups throughout the study. Growth was comparable in BF. No relevant safety issues were observed. To conclude, eHF meets infant requirements for adequate growth during the first six months of life and can be considered safe and suitable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Evangelisches Waldkrankenhaus Spandau, Stadtrandstr. 555, 13589 Berlin, Germany.
- HiPP GmbH & Co. Vertrieb KG, Georg-Hipp-Str. 7, 85276 Pfaffenhofen an der Ilm, Germany.
- Brandenburg Medical School Theodor Fontane (MHB), Fehrbelliner Str. 38, 16816 Neuruppin, Germany.
Förderung
- HiPP GmbH & Co. Vertrieb KG
Zitieren
APA
Otten, L., Schelker, E., Petersen, H., Nomayo, A., Fleddermann, M., Arendt, B. M., Britzl, T., Haberl, E. M., Jochum, F., & HASI Study Group (2023). Safety and Suitability of an Infant Formula Manufactured from Extensively Hydrolysed Protein in Healthy Term Infants. Nutrients. https://doi.org/10.3390/nu15081901
Vancouver
Otten L, Schelker E, Petersen H, Nomayo A, Fleddermann M, Arendt BM, et al. Safety and Suitability of an Infant Formula Manufactured from Extensively Hydrolysed Protein in Healthy Term Infants. Nutrients. 2023. doi:10.3390/nu15081901
BibTeX
@article{Otten2023,
author = {Otten, Lindsey and Schelker, Elisabeth and Petersen, Hanna and Nomayo, Antonia and Fleddermann, Manja and Arendt, Bianca M and Britzl, Theresa and Haberl, Elisabeth M and Jochum, Frank and HASI Study Group, HASI Study Group},
title = {Safety and Suitability of an Infant Formula Manufactured from Extensively Hydrolysed Protein in Healthy Term Infants},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15081901}
}
EUVIMED